Pharmaceuticals
Aquavit Celebrates Judgment Imposing Permanent Ban On Counterfeiters
NEW YORK, Nov. 4, 2022 /PRNewswire/ -- Aquavit Pharmaceuticals, Inc. ("Aquavit") secured a long-awaited and much-deserved judgment against counterfeiters. After nearly four years of court proceedings, the Honorable Valerie E. Caproni ofthe United States District Court for the Southern District o...
2022-11-04 01:37
4305
Kira Pharmaceuticals Presents Complete Data from Phase 1 SYNERGY-1 Trial of KP104 at American Society for Nephrology Kidney Week 2022
Biomarker data demonstrates proof-of-concept for KP104's dual-targeting mechanism via dose-dependent inhibition of alternative and terminal pathways and supports intravenous and subcutaneous administration of KP104 in phase 2 studies CAMBRIDGE, Mass. and SUZHOU, JIANGSU, China, Nov. 3, 2022 /PRN...
2022-11-03 21:30
3853
Malaysia Seeks Strategic Global Partnerships to Accelerate Its Growth Trajectory As A Preferred Healthcare Destination
Explore the potentials of Malaysia Healthcare at World Travel Market London 2022
LONDON, Nov. 3, 2022 /PRNewswire/ -- Malaysia Healthcare is strengthening its
global proposition for preventive healthcare via strategic partnerships at the
World Travel Market 2022 ("WTM") in London.
2022-11-03 18:16
3000
First in-human use of OncoRes Medical's cancer imaging system successful
Quantitative Micro-Elastography (QME) Imaging System published in peer reviewed Cancer Research PERTH, Australia, Nov. 3, 2022 /PRNewswire/ -- OncoRes Medical today announces positive data from the first in-cavity use of its Quantitative Micro-Elastography (QME) Imaging System. The study, titled...
2022-11-03 06:00
2570
Turn Biotechnologies Names 25-year Biotech Industry Veteran Richard Peterson Chief Financial Officer
Seasoned Executive has Successful Track Record Working with Global Investors to Raise Billions of Dollars MOUNTAIN VIEW, Calif., Nov. 2, 2022 /PRNewswire/ -- Turn Biotechnologies, a cell rejuvenation company developing novel mRNA medicines to cure untreatable, age-related conditions, today annou...
2022-11-02 21:00
4035
Daewoong Pharmaceutical Presents Phase 3 Clinical Trial Results of New Diabetes Treatment 'Enavogliflozin' and Roadmap to Enter 50 Countries by 2030
* Highly anticipated to be an effective therapeutic for its excellent efficacies in reducing blood glucose levels and safety SEOUL, South Korea, Nov. 2, 2022 /PRNewswire/ -- Daewoong Pharmaceutical (Daewoong), the South Korea -based global healthcare company, announced the phase III clinical tri...
2022-11-02 09:00
3015
Ascletis Announces U.S. IND Filing of Oral 3CLpro Inhibitor ASC11 for COVID-19
-- ASC11 is an in-house discovered oral small molecule drug candidate, targeting 3-chymotrypsin like protease (3CLpro) -- In antiviral cellular assays with infectious SARS-CoV-2, ASC11 demonstrated higher potency against SARS-CoV-2 than other 3CLpro inhibitors including Nirmatrelvir, S-217622, P...
2022-11-02 08:10
3843
SK pharmteco appoints Joerg Ahlgrimm as CEO to spearhead the next phase of company growth and innovation
- Joerg Ahlgrimm brings 25 years of expertise in pharmaceuticals and innovative cell and gene therapies - SK pharmteco expands pharmaceutical drug production and advances cell and gene therapy production - Annual sales expected to exceed KRW 1 trillion in 2022 FRANKFURT, Germany, Nov. 2, 2022 /PR...
2022-11-02 02:00
2882
Henlius' Novel Anti-PD-1 mAb HANSIZHUANG (Serplulimab) Receives NMPA Approval for the Treatment of sqNSCLC
SHANGHAI, Nov. 1, 2022 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696. HK) announced that its first self-developed innovative anti-PD-1 monoclonal antibody (mAb) HANSIZHUANG (generic name: serplulimab injection), in combination with carboplatin and albumin-bound paclitaxel for the first-lin...
2022-11-01 21:32
5183
Hummingbird Bioscience to Attend the Credit Suisse 31st Annual Healthcare Conference
SAN FRANCISCO, HOUSTON and SINGAPORE, Nov. 1, 2022 /PRNewswire/ -- Hummingbird Bioscience, a data-driven precision biotherapeutics company discovering and developing transformative biologic medicines for hard-to-treat diseases, today announced that Chief Financial OfficerJosh House and Chief Deve...
2022-11-01 20:00
2177
Karyopharm and Menarini Group Announce Orphan Medicinal Product Designation from the European Commission for Selinexor for the Treatment of Myelofibrosis
NEWTON, Mass. and FLORENCE, Italy, Nov. 1, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, and the Menarini Group ("Menarini"), a privately-held, leading international pharmaceutical company, today anno...
2022-11-01 19:40
3490
Citeline and Norstella Complete Merger to Form a $5 Billion Global Pharmaceutical Technology Company
With more than 1,600 employees across the globe, the new organization is now one of the world's largest pharma intelligence solutions providers on the market YARDLEY, Pa., Nov. 1, 2022 /PRNewswire/ -- Norstella, a global leader with end-to-end solutions that smooth access to life-saving therapies...
2022-11-01 19:00
5168
Pervistop®, the once-daily supplement specifically designed to manage persistent HPV, is now available for exclusive distribution rights worldwide.
Lo.Li. Pharma International to unveil an innovative new product at CPHI Frankfurt, which has already gained the interest of numerous distribution partners. Pervistop® promises to be an extremely effective tool in the management of an exceedingly unpredictable disease. FRANKFURT, Germany, Nov. 1,...
2022-11-01 16:00
4035
Gerresheimer AG and Stevanato Group present EZ-fill Smart™, a new and innovative Ready-To-Fill Vial Platform
DÜSSELDORF, Germany and PIOMBINO DESE, Italy, Nov. 1, 2022 /PRNewswire/ -- Gerresheimer AG, a leading global provider of healthcare & beauty and drug delivery systems for pharma, biotech and cosmetics and Stevanato Group S.p.A., a global provider of drug containment, drug delivery and diagnostic ...
2022-11-01 15:00
2069
RemeGen Releases Phase II Clinical Study Data for Treatment of Myasthenia Gravis in Chinese Patients
YANTAI, China, Nov.1, 2022 /PRNewswire/ -- RemeGen Co., Ltd. ("RemeGen" or "the Company") (9995.HK, SHA: 688331), a commercial-stage biotechnology company, recently released data from the Phase II clinical study of its proprietary novel fusion protein Telitacicept for the treatment of myasthenia ...
2022-11-01 12:12
3774
Codex Genetics to Offer Guardant Health's Precision Oncology Tests in Hong Kong and Macau
HONG KONG, Nov. 1, 2022 /PRNewswire/ -- Codex Genetics today announced an exclusive collaboration with Guardant Health Asia,Middle East and Africa (AMEA) to offer comprehensive genomic profiling (CGP) tests to hospitals and clinics in Hong Kong and Macau. As part of the collaboration, Gua...
2022-11-01 11:21
4777
Antengene Receives U.S. FDA Clearance of IND Application for Phase I Trial of Small Molecule ERK1/2 Inhibitor ATG-017 in Patients with Advanced Solid Tumors
* ATG-017 is a small molecule ERK1/2 inhibitor and Antengene has obtained exclusive global rights to develop, commercialize and manufacture ATG-017. * IND clearance enables Antengene to initiate the combination portion of the Phase I "ERASER" clinical trial inthe United States (U.S.) to evalua...
2022-10-31 20:22
3735
Xinhua Silk Road: Cloud + offline fair injects new vitality into National TCM Materials & Pharmaceuticals Trade Fair
BEIJING, Oct. 31, 2022 /PRNewswire/ -- The 53rd National Traditional Chinese Medicine (TCM) Materials and Pharmaceuticals Trade Fair, a vital platform to promote communication in medical field inChina, bore witness to how online-offline integration greatly boosted trading on the opening day on Fr...
2022-10-31 19:00
5718
Innovent Announces First Patient Dosing in Australia in Phase I Study of IBI343 (Recombinant anti-Claudin18.2 Monoclonal Antibody-drug Conjugate) in Patients with Advanced Solid Tumors
ROCKVILLE, Md. and SUZHOU, China, Oct. 30, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmolog...
2022-10-31 08:00
4290
Samyang Holdings' Lafullen Makes Splash in Korean Medical Aesthetics Market
- Successfully demonstrated Lafullen's safety and efficacy at autumn medical symposiums - Shared treatment protocols and clinical cases to lecturers by specialist - Continued to develop evidence-based marketing to Asian markets SEOUL, South Korea, Oct. 31, 2022 /PRNewswire/ -- Samyang Holdings ...
2022-10-31 08:00
4083
Week's Top Stories
Most Reposted
SMU School of Accountancy launches Applied AI Track for next generation of accounting and finance professionals
[Picked up by 282 media titles]
2026-10-07 11:50DayOne Files Registration Statement for Proposed Initial Public Offering
[Picked up by 279 media titles]
2026-10-06 05:28Agoda Partners with Marina Bay Sands on Bespoke Flagship Store for Experience-Led Travel
[Picked up by 277 media titles]
2026-10-08 09:50
New Asia Forum Targets US$30 Billion in Investment into the New Asia at Its Inaugural Edition in Bali
[Picked up by 275 media titles]
2026-10-09 13:21CHANDO Group Presents 20 Research Papers at IFSCC 2026 Congress in Perth
[Picked up by 261 media titles]
2026-10-06 11:40
Most Read
Nuix Neo Generative AI Framework
2026-10-08 08:02
9663
DayOne Files Registration Statement for Proposed Initial Public Offering
2026-10-06 05:28
9485
Silicon Quantum Computing Named to Fast Company's 2026 Next Big Things in Tech List
2026-10-06 19:38
8791
